Skip to main content
. 2004 Jun 4;53(12):1111–1118. doi: 10.1007/s00262-004-0551-7

Table 4.

Time to progression (TTP) of metastatic melanoma and renal cell carcinoma (RCC) patients vaccinated with dendritic cell–tumor cell hybrids every 6 weeks until disease progression or lack of tumor cells for vaccine preparation. OR objective response, SD Stable disease, DP disease progression

Response Melanoma RCC
n TTPa n TTP
OR 0 3 6.7 (5–21)
SD 8 11.1 (4–17+) 14 8.4 (3.7–19+)
DP 3 2.6 (2.3–2.7) 2 2.7 (2.6–2.8)
Overall 11 5.6 19 6.7

aMedian time to progression in months (range)